01.03.2026, 1480 Zeichen
EVN: Austrian utility company EVN reported results for the first quarter of business year 2025/2026. Revenue recorded by the EVN Group rose by 3.3% to EUR 830.7m in the first quarter of 2025/26, above all due to regulatory price effects in the distribution network companies in Lower Austria and Bulgaria. EBITDA declined by 2.2% year-on-year to EUR 247.4m. The high volume of investments led to an increase of 8.4% in scheduled depreciation and amortisation to EUR 94.2m. EBIT was 7.8% lower year-on-year at EUR 153.2m. Generation coefficients both for wind and water were - with the exception of water flows in North Macedonia - clearly below the long-term average and previous year in all markets.
EVN: weekly performance:
FACC: Aerospace supplier FACC AG is looking back on a successful 2025 financial year and is consistently continuing its sustainable growth course. Group revenue rose to EUR 984.4 million in the 2025 financial year (2024: EUR 884.5 million). Despite high site costs in Austria due to a sharp increase in personnel and energy costs compared to the global environment, the operating result (EBIT) increased noticeably by 49.4% to EUR 42.3 million. The EBIT margin thus improved from 3.2% to 4.3%. Particularly pleasing: All divisions – Aerostructures, Engines & Nacelles and Cabin Interiors – made a positive contribution to earnings.
FACC: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/02/2026)
Wiener Börse Party #1189: ATX startet schwächer ins 2. Halbjahr, Andritz feiert in der Wiener Börse, Erste Group heuer schon +10 Mrd.
Aktien auf dem Radar:AT&S, Telekom Austria, Frequentis, Semperit, Amag, EuroTeleSites AG, Rosgix, Polytec Group, Bawag, Flughafen Wien, Verbund, Andritz, FACC, Gurktaler AG Stamm, Gurktaler AG VZ, Rath AG, Stadlauer Malzfabrik AG, BKS Bank Stamm, Josef Manner & Comp. AG, CPI Europe AG, Österreichische Post, UBM.
Marinomed
Marinomed hat die Vision, das Leben von Patienten, die an Krankheiten mit unzureichenden Behandlungsmöglichkeiten leiden, in zwei wichtigen therapeutischen Bereichen nachhaltig zu verbessern: Virologie und Immunologie.
>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten